7月10日，基蛋生物今日收盘8.19元，上涨1.11%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到20.57倍，创21天以来新低，总市值41.54亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13基蛋生物20.5718.571.5541.54亿行业平均 51.4049.164.55107.36亿行业中值37.2738.502.4952.03亿1九安医疗10.2810.390.81173.44亿2英科医疗 11.0011.850.98173.72亿3新华医疗14.3613.311.1792.03亿4振德医疗15.3714.490.9855.79亿5奥美医疗 15.4815.171.5955.92亿6山东药玻15.5615.611.79147.19亿7康德莱16.1116.131.3434.72亿8奥泰生物 16.4317.331.3352.40亿9九强生物16.6315.462.0482.37亿10维力医疗16.6817.341.9638.04亿11安杰思 17.4017.612.1151.66亿12安图生物18.9218.052.43215.66亿 来源：金融界 从行业市盈率 ...

导读： 生态环境部发布4项国家生态环境标准，2025年8月1日实施，规范大气颗粒物来源解析，涉及扬尘采样、滤膜称量及糖类物质测定。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 为加强大气污染防治，规范环境空气颗粒物来源解析工作，生态环境部批准《环境空气 颗粒物来源解析 开放源扬尘采样技术规范》等4项标准 为国家生态环境标准，并予发布，2025年8月1日起实施。 一、《 环境空 气 颗粒物来源解析 开放源扬尘采样技术规范》（HJ 1411-2025） 本标准为首次发布。 本标准主要起草单位：中国环境监测总站、南开大学、西安市环境监测站、天津市生态环境监测中心、福建省福州环境监测中心站。 本标准规定了开放源扬尘（土壤扬尘、道路扬尘、施工扬尘、堆场扬尘、混合扬尘）采样的技术内容和要求。 本标准适用于环境空气颗粒物来源解析工作中开放源扬尘的采样。 二、 《环境空气 颗粒物来源解析 颗粒物滤膜自动称量技术规范》（HJ 1412-2025） 三、 《环境空气 颗粒物来源解析 离子色谱法测定颗粒物中左旋葡聚糖、甘露聚糖和半乳聚糖》（HJ 1413-2 ...

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, predicting a reversal trend in 2025 [4] Core Viewpoints - The innovative drug sector is experiencing strong performance driven by multiple factors, including the completion of quarterly portfolio adjustments, increased policy support from the National Healthcare Security Administration (NHSA) and the National Health Commission, and significant collaborations in the industry [1][11] - The NHSA and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, which will accelerate the commercialization of domestic innovative products and create a positive cycle of profitability and strong R&D investment [20][21] - The report highlights the potential of dual/multi-target antibodies in cancer treatment and innovative drugs addressing unmet clinical needs in chronic diseases as key investment opportunities [1][4] Summary by Sections Innovative Drugs - The innovative drug sector remains the main investment line, with a focus on dual/multi-target antibodies for various cancers and chronic diseases [1][11] - AstraZeneca is in talks for a collaboration worth up to $15 billion for the AK112 drug, which has catalyzed strong performance in related stocks [1] Pharmaceutical Sector - The NHSA's new measures will direct more healthcare resources towards innovative drugs, enhancing their commercialization and profitability [20][21] - The report notes that since 2018, 149 innovative drugs have been included in the healthcare insurance directory, significantly increasing the proportion of new drugs covered [22] Biologics - Changchun High-tech's new drug, Vuxin Qibai monoclonal antibody, has been approved for treating acute gout arthritis, marking a significant advancement in biologics [29][34] - The drug shows rapid onset of action and a substantial reduction in recurrence risk, highlighting its clinical significance [33][34] Traditional Chinese Medicine - Lingrui Pharmaceutical's new indication for its nasal spray is expected to boost sales, with ongoing efforts to expand hospital coverage and OTC sales [38][41] Medical Devices - The report emphasizes policy support for high-end medical devices, predicting accelerated commercialization in various segments such as medical robots and AI [3][4] Medical Services - Recent policies to enhance maternity benefits are expected to stimulate demand in related services [3][4]

Corporate Announcements - Aerospace Hongtu's controlling shareholder plans to transfer 5.1% of the company's shares, totaling 13.33 million shares at a price of 19 yuan per share, amounting to 253 million yuan [3] - Haitai Development intends to transfer 100% equity of its subsidiary for 90.66 million yuan, which is part of its strategic transformation to optimize asset structure [4] - G-Biosciences plans to invest approximately 150 million yuan to build an intelligent production and R&D base, expected to be completed by 2028 [5] - New China Life Insurance intends to invest 11.25 billion yuan to subscribe to a private fund, which has a total scale of 22.5 billion yuan [6] - Huaming Equipment has increased its share repurchase fund limit from 200 million yuan to 250 million yuan [7] Performance Updates - Jinxinnong reported a 1.23% year-on-year decline in pig sales revenue for the first half of 2025, totaling 763 million yuan [9] - Tianbang Foods reported a 4.01% month-on-month decline in June sales revenue for commodity pigs, totaling 675 million yuan [10] - GAC Group's June automobile sales were 150,100 units, a year-on-year decrease of 8.22% [11] - Pulit expects a net profit of 200 million to 240 million yuan for the first half of 2025, a year-on-year increase of 38.88% to 66.65% [12] - Zhuyue Group anticipates a net profit of 560 million to 650 million yuan for the first half of 2025, a year-on-year increase of 50.97% to 75.23% [14] - Xindong Lianke expects a net profit of 138 million to 169 million yuan for the first half of 2025, a year-on-year increase of 144.46% to 199.37% [15] - Zhongce Rubber expects a net profit of 2.24 billion to 2.38 billion yuan for the first half of 2025, a year-on-year decrease of 6.3% to 11.81% [16] - ST Sitong anticipates a net loss of 11 million to 17 million yuan for the first half of 2025, compared to a loss of 9.08 million yuan in the same period last year [17] Major Contracts - Hongsheng Huayuan's subsidiary is expected to win a bid for a Southern Power Grid project worth approximately 1.127 billion yuan, accounting for 11.12% of the company's 2024 revenue [19] - Times New Materials signed contracts worth approximately 2.711 billion yuan for wind turbine blade sales in the second quarter of 2025 [20] Shareholding Changes - Guojian Group's controlling shareholder reduced its holdings of convertible bonds by 900,000 units, accounting for 11.25% of the total issuance [22]

7月4日，迪瑞医疗今日收盘14.03元，下跌1.06%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到106.87倍，总市值38.26亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迪瑞医疗106.8726.961.8538.26亿行业平均 51.0548.784.55107.12亿行业中值36.6236.522.5051.67亿1九安医疗10.2610.380.81173.21亿2英科医疗 10.4711.290.93165.45亿3新华医疗14.4313.381.1892.52亿4奥美医疗15.3215.011.5755.35亿5山东药玻 15.3915.431.77145.53亿6振德医疗15.4714.580.9856.17亿7康德莱15.7315.741.3033.89亿8维力医疗 16.4917.141.9337.60亿9九强生物16.4915.332.0281.66亿10奥泰生物16.6117.511.3452.96亿11安杰思 17.6117.812.1352.26亿12安图生物18.8317.982.42214.74亿 来源：金融界 迪瑞医疗科技股份有限公司的 ...

基蛋生物（603387）公告，公司计划投资1.5亿元建设智能化生产研发基地，包含土地价款、建筑主体 工程及配套设施工程费用。项目占地面积约40010.27平方米，总建筑面积约65538.81平方米，主要建设 内容为四层综合厂房、高标准仓储中心及配套研发办公设施。项目建成后，将形成化学发光、生化、血 球等产品线仪器及试剂的产能。公司已取得项目所需建设用地以及相关许可证书，预计2028年建设完 成。 ...

事件:公司发布2024年年度报告及2025年一季度报告。2024年实现营业收入20.12亿元(2.0296),归母净利 润3.02亿元(-15.06%6)扣非净利润2.87亿元(+30.84%)，经营性现金流5.30亿元。2024年04实现营业收入 6.18亿元(+21.57%)，归母净利润0.83亿元(+18.43%6)，扣非净利润0.80 亿元(+76.60%)2025年01实现营业 收入4.18亿元(-3.13%)，归母净利润0.10亿元(-84.6396)，扣非净利润0.37亿元(-35.44%6)，经营性现金流 0.06亿元。 保持高水平研发投入，自主产品解决方案愈发丰富。2024年公司研发投入3.38亿元(+3.84%)，占营业收 入比例16.80%;202501公司研发投入0.67亿元(-20.56%6)，占营业收入比例16.08%。2024年公司自主研发 的iBC2000全自动生化分析仪国内注册获批及国际CE注册获证，其速度可达2000T/h，[SE离子枪测模块 可同时测试三项，最高速度达成1200T/h:试剂方面，2024年公司在自身免疫性肝病、天疱疮、不孕不 育、抗磷脂综合征、高血压等新增 ...

作为一家专注于为全球制药和生物医药行业提供专业高效的小分子及新分子类型药物的平台型高新技术 企业，近年来，皓元医药持续加速新产品管线布局和技术迭代，市场竞争力不断提升。 2025年一季度，皓元医药实现营业收入6.06亿元，同比增长20.05%；净利润6238.44万元，同比增长 272.28%。报告期内，皓元医药的研发费用为5371.37万元，占营业收入的比例为8.86%。 两次对子公司债转股增资 资料显示，安徽皓元成立于2017年6月，是皓元医药IPO募投项目"安徽皓元生物医药研发中心建设项 目""安徽皓元年产121.095吨医药原料药及中间体建设项目（一期）"的实施主体。 据皓元医药介绍，因公司实施上述IPO募投项目，安徽皓元作为募投项目实施主体向公司募集资金专户 请款，安徽皓元收到公司支付的募集资金款项后，根据签署的合同及项目进度及时向供应商完成支付， 上述两大项目已分别于2021年、2024年结项。 长江商报消息 ●长江商报记者 徐佳 为进一步提升子公司的竞争优势，缓解资金压力，皓元医药（688131.SH）再次以债转股的方式实施增 资。 7月1日晚间，皓元医药公告称，公司拟以债转股方式向全资子公司安 ...

7月2日【立方招采通】标讯亮点包括工程建设、医疗药械、商务服务、设备采购等项目。其中：山姆会 员商店建设施工项目和南阳市第六人民医院医疗设备采购项目（第一批）可重点关注。 预算金额：318.00万元 项目概况：采购全数字化彩色多普勒超声诊断仪、全自动生化免疫流水线、全自动分枝杆菌培养监测仪 等21项设备 提交投标文件截止时间：2025年7月24日9时 郑州东沃管理有限公司发布山姆会员商店建设施工项目招标计划，计划招标时间为2025年7月，合同估 算价为2.5亿元；该工程监理项目同日启动招标，合同估算价为125万元。项目位于郑州市郑东新区如意 东路东、如意河东十街北，总用地面积29338.4平方米（约44.01亩）。其中商业用地21508.4平方米，总 建筑面积61600平方米。该地块于今年1月由郑州东沃管理有限公司以2.03亿元竞得；今年3月中国建筑 西南设计研究院成功中标该项目建筑方案设计。 南阳市第六人民医院医疗设备采购项目（第一批）资金来源为财政资金，采购内容为：全自动细菌鉴定 及药敏分析系统、全自动流式细胞仪、全自动细菌分散计数仪、全自动微生物培养系统、全自动医用 PCR检测系统等21套设备，包含医疗 ...

导读： 作为医疗临床检验仪器及配套试剂的供应商，迪安致力于将国际前沿的医学检验技术和设备引进中国，获得德国Roche(罗氏诊断)、德国QIAGEN (凯杰生 物)、德国科宝等全球著名企业产品代理资质。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 | 各中心 | 设备类别 | 参数 | 数量 | | --- | --- | --- | --- | | | | 检测速度大于2000测试/小时 | | | | | 试剂位≥120个 | | | | 1.全自动生化分析系统 | 样本位≥250个 | 1套 | | | | (按照实际需求提供) | | | | 2、全自动化学发光免疫分 | 检测速度大于600测试/小时 试剂位≥30个 | | | | | | 1套 | | | 析系统 | 样本位≥160个 | | | | | (按照实际需求提供) 干化学测试模式≥200个/每 | | | | | 小时 | | | | 3.全自动尿液分析系统 | 有形成分测试模式≥100个/ | 1套 | | | | 每小时: | | | | | (按照实际需求提供 ...